Cirevetmab

• Description:

  Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator[1].

• Product Name Alternative:

  ZTS-00521426

• UNSPSC:

  12352203

• Target:

  TGF-beta/Smad

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Stem Cell/Wnt; TGF-beta/Smad

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cirevetmab.html

• Solubility:

  H2O

• Smiles:

  [Cirevetmab]

• References & Citations:

  [1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 35, No. 4, 2021.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported

• CAS Number:

  [2473240-98-9]